The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling

Most patients with multiple myeloma treated with current therapies, including immunomodulatory drugs, eventually develop relapsed/refractory disease. Clinical activity of lenalidomide relies on degradation of Ikaros and the consequent reduction in IRF4 expression, both required for myeloma cell surv...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Haematologica
Hlavní autoři: Díaz, Tania, Rodríguez, Vanina, Lozano, Ester, Mena, Mari-Pau, Calderón, Marcos, Rosiñol, Laura, Martínez, Antonio, Tovar, Natalia, Pérez-Galán, Patricia, Bladé, Joan, Roué, Gaël, de Larrea, Carlos Fernández
Médium: Artigo
Jazyk:Inglês
Vydáno: Ferrata Storti Foundation 2017
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5622862/
https://ncbi.nlm.nih.gov/pubmed/28751557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2017.164632
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky